LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

158 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-23

Study Completion Date

2023-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma

NCT01820364

Melanoma

TERMINATED PHASE2

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453

Melanoma

COMPLETED PHASE3

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

NCT01894672

Melanoma

COMPLETED PHASE2

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

NCT01320085

BRAF or NRAS Mutant Metastatic Melanoma

COMPLETED PHASE2

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

NCT02094872

Recurrent Melanoma Stage IIIA Melanoma Stage IIIB Melanoma +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study consists of two parts: in Part I/Run-In, patients naïve to selective BRAF and MEK inhibitors will be treated with the LGX818/MEK162 combination until disease progression (as defined per RECIST v1.1). Based on the genetic analysis of a tumor biopsy obtained at that time, patients will enter Part II of the study for tailored combination treatment in one of four arms of LGX818/MEK162 + either BKM120, BGJ398, INC280 or LEE011 Patients with BRAF mutant melanoma treated by LGX818/MEK162 combination in other studies can be enrolled directly in Part II of CLGX818X2109 after relapse.

Dose-escalations in the combination arms for which no MTD has been established will be based on the recommendations of a Bayesian logistic regression model guided by an escalation with overdose control criterion

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LGX818 + MEK162

Group Type EXPERIMENTAL

LGX818

Intervention Type DRUG

Combination of LGX818 and MEK162 (Part I)

MEK162

Intervention Type DRUG

Combination of LGX818 and MEK162 (Part I)

LGX818 + MEK162 + LEE011

Group Type EXPERIMENTAL

LEE011

Intervention Type DRUG

Combination of LGX818 + MEK162 + LEE011 (Part II)

LGX818 + MEK162 + BGJ398

Group Type EXPERIMENTAL

BGJ398

Intervention Type DRUG

Combination of LGX818 + MEK162 + BGJ398 (Part II)

LGX818 + MEK162 + BKM120

Group Type EXPERIMENTAL

BKM120

Intervention Type DRUG

Combination of LGX818 + MEK162 + BKM120 (Part II)

LGX818 + MEK162 + INC280

Group Type EXPERIMENTAL

INC280

Intervention Type DRUG

Combination of LGX818 + MEK162 + INC280 (Part II)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LEE011

Combination of LGX818 + MEK162 + LEE011 (Part II)

Intervention Type DRUG

BGJ398

Combination of LGX818 + MEK162 + BGJ398 (Part II)

Intervention Type DRUG

BKM120

Combination of LGX818 + MEK162 + BKM120 (Part II)

Intervention Type DRUG

INC280

Combination of LGX818 + MEK162 + INC280 (Part II)

Intervention Type DRUG

LGX818

Combination of LGX818 and MEK162 (Part I)

Intervention Type DRUG

MEK162

Combination of LGX818 and MEK162 (Part I)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Histologically confirmed diagnosis of unresectable stage III or metastatic melanoma (stage IIIC to IV per American Joint Committee on Cancer \[AJCC\])
* Documented evidence of BRAF V600 mutation.
* Newly obtained tumor biopsy at baseline, and patient agrees to a mandatory biopsy at the time of progression, if not medically contraindicated.
* Evidence of measurable disease, as determined by RECIST v1.1.

Exclusion Criteria

* Symptomatic brain metastases. Patients previously treated or untreated for brain metastases that are asymptomatic in the absence of corticosteroid therapy or on a stable dose of steroids for four weeks are allowed to enroll. Brain metastases must be stable at least 4 weeks with verification by imaging (e.g. brain MRI completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive enzyme inducing anti-epileptic drugs.
* Patients who have developed brain metastases during Part I of the study may continue to Part II upon discussion with Novartis Medical Monitor. The brain metastasis must be either asymptomatic or treated and stable for at least 4 weeks and on a stable or tapering dose of steroids for at least 2 weeks. Patients with brain metastasis are not eligible for the combination with LEE011.
* Known acute or chronic pancreatitis.
* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes);
* Clinically significant cardiac disease including any of the following:
* CHF requiring treatment (NYH grade ≥ 2),
* LVEF \< 50% as determined by MUGA scan or ECHO
* History or presence of clinically significant ventricular arrhythmias or atrial fibrillation
* Clinically significant resting bradycardia
* Unstable angina pectoris ≤ 3 months prior to starting study drug
* Acute Myocardial Infarction (AMI) ≤ 3 months prior to starting study drug,
* QTcF \> 480 msec. Patients with any of the following laboratory values at

Screening/baseline:

* Absolute neutrophil count (ANC) \<1,500/mm3 \[1.5 x 109/L\]
* Platelets \< 100,000/mm3 \[100 x 109/L\]
* Hemoglobin \< 9.0 g/dL
* Serum creatinine \>1.5 x ULN or calculated or directly measured CrCl \< 50% LLN (lower limit of normal)
* Serum total bilirubin \>1.5 x ULN
* AST/SGOT or ALT/SGPT \> 2.5 x ULN, or \> 5 x ULN if liver metastases are present

LGX818/MEK162/BKM120:

* Patients with fasting glucose \> 120 mg/dL or 6.7 mmol/L, and HbA1c \> 8 %.
* Patient has any of the following mood disorders as judged by the

Investigator or a Psychiatrist:

* Patient has a score ≥ 12 on the PHQ-9 questionnaire
* Patient has ≥ CTCAE grade 3 anxiety

LGX818/MEK162/BGJ398:

* History and/or current evidence of significant ectopic mineralization/ calcification with the exception of calcified lymph nodes and asymptomatic vascular calcification.
* Current evidence of corneal disorder/ keratopathy incl. but not limited to bullous/ band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivits etc., confirmed by ophthalmologic examination

LGX818/MEK162/LEE011:

* Patients with uncontrolled hypertension (please refer to WHO-ISHguidelines) are excluded from study.
* QTcF \>450 ms for males and \>470 ms for females Congenital long QT syndrome or family history of unexpected sudden cardiac death and/or hypokalemia CTCAE Grade ≥ 3 and magnesium levels below the clinically relevant lower limits at study entry
* Current evidence of brain metastasis or brain metastasis detected by mandatory CT/MRI at screening
* PT/INR or aPTT \> 1.5xULN

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.